Compare · AZN vs ROIV
AZN vs ROIV
Side-by-side comparison of AstraZeneca PLC (AZN) and Roivant Sciences Ltd. (ROIV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and ROIV operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $261.92B, about 10.6x ROIV ($24.82B).
- Over the past year, AZN is down 10.3% and ROIV is up 201.6% - ROIV leads by 211.9 points.
- AZN has been more active in the news (15 items in the past 4 weeks vs 14 for ROIV).
- AZN has more recent analyst coverage (25 ratings vs 18 for ROIV).
- Company
- AstraZeneca PLC
- Roivant Sciences Ltd.
- Price
- $168.85-0.24%
- $34.50+1.65%
- Market cap
- $261.92B
- $24.82B
- 1M return
- -5.56%
- +13.47%
- 1Y return
- -10.32%
- +201.57%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- News (4w)
- 15
- 14
- Recent ratings
- 25
- 18
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Roivant Sciences Ltd.
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- AstraZeneca downgraded by HSBC Securities
- SEC Form 6-K filed by AstraZeneca PLC
- Officer Sharma Mani was granted 2 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,265 units (SEC Form 4)
- The Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in Parallel
- Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 11-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
Latest ROIV
- CEO Gline Matthew covered exercise/tax liability with 76,171 shares, decreasing direct ownership by 0.46% to 16,659,945 units (SEC Form 4) (for withholding tax)
- Director Fitzgerald Meghan exercised 10,000 shares at a strike of $8.80 and sold $349,000 worth of shares (10,000 units at $34.90) (SEC Form 4)
- President and Vant Chair Torti Frank covered exercise/tax liability with 40,310 shares, decreasing direct ownership by 0.30% to 13,536,202 units (SEC Form 4) to cover withholding tax
- President & CIO Sukhatme Mayukh covered exercise/tax liability with 46,878 shares, decreasing direct ownership by 0.25% to 18,630,739 units (SEC Form 4) to satisfy tax liability
- Director Epperly Melissa B, sold $610,252 worth of shares (17,750 units at $34.38) and exercised 17,750 shares at a strike of $4.46 (SEC Form 4)
- Director Manchester Keith S sold $56,444,076 worth of shares (1,638,163 units at $34.46), decreasing direct ownership by 10% to 1,748,403 units (SEC Form 4)
- Director Gold Daniel Allen sold $49,354,076 worth of shares (1,438,163 units at $34.32) (SEC Form 4)
- Director by Deputization Qvt Financial Lp sold $49,354,076 worth of shares (1,438,163 units at $34.32) (SEC Form 4)
- SEC Form 144 filed by Roivant Sciences Ltd.
- SEC Form 144 filed by Roivant Sciences Ltd.